Efficacy and Safety of Phase 1 of Very Low Energy Ketogenic Therapy (VLEKT) in Subjects with Obesity and Mild Renal Impairment
Nutrients,
Год журнала:
2025,
Номер
17(4), С. 721 - 721
Опубликована: Фев. 18, 2025
Background:
Obesity
impairs
renal
function
through
direct
mechanisms,
such
as
proinflammatory
adipocytokine
production,
and
indirect
including
obesity-related
comorbidities.
Despite
the
increasing
prevalence
of
obesity
chronic
kidney
disease
(CKD),
clinical
guidelines
for
their
combined
management
remain
lacking.
Very
Low
Energy
Ketogenic
Therapy
(VLEKT)
has
demonstrated
efficacy
in
weight
loss,
but
evidence
on
its
safety
individuals
with
mild
impairment
is
limited.
This
study
aimed
to
assess
Phase
1
VLEKT
impairment.
Methods:
cross-sectional
included
73
overweight
or
(mean
age
53.7
±
8.8
years;
BMI
35.3
4.2
kg/m2)
an
estimated
glomerular
filtration
rate
(eGFR)
at
least
60
mL/min/1.73
m2
(evaluated
using
CKD-EPI
equation).
Anthropometric
(weight,
BMI,
waist
circumference)
biochemical
parameters
(fasting
plasma
glucose,
insulin,
cholesterol
profile,
triglycerides,
AST,
ALT,
urea)
were
collected
baseline
after
45
(±2)
days
VLEKT.
Results:
At
baseline,
54.8%
participants
had
eGFR
<90
m2,
while
45.2%
≥
90
no
significant
differences
sex
distribution.
After
VLEKT,
both
groups
showed
reductions
(p
<
0.001),
circumference
fasting
glucose
≤
0.004),
insulin
HOMA-IR
total
LDL
LDL/HDL
ratio
0.002),
triglycerides
0.009),
AST
0.034),
ALT
0.009).
Notably,
significantly
increased
changes
observed
those
m2.
Conclusions:
could
effectively
promote
loss
metabolic
improvements
without
compromising
function,
even
Further
research
warranted
confirm
outcomes
across
all
protocol
phases.
Язык: Английский
Advancing Obesity Management: the Very Low-Energy Ketogenic therapy (VLEKT) as an Evolution of the “Traditional” Ketogenic Diet
Current Obesity Reports,
Год журнала:
2025,
Номер
14(1)
Опубликована: Апрель 3, 2025
This
narrative
review
comprehensively
analyzes
VLEKT
as
an
advanced
nutritional
strategy
for
obesity
management.
The
focus
is
on
the
beneficial
effects
key
disease
organs,
such
adipose
tissue
and
liver,
well
modulation
of
intestinal
permeability
its
fundamental
role
in
influencing
gut
microbiota
inflammatory
pathways.
impact
obesity-related
comorbidities,
including
metabolic
syndrome,
cardiovascular
disease,
endocrine
disorders,
dysfunction-associated
steatotic
liver
(MASLD),
neurological
kidney
alterations,
also
investigated.
Moreover,
to
assess
wider
application
treatment,
combination
ketogenic
regimes
with
additional
strategies
physical
activity,
bariatric
surgery,
digital
health
technologies
examined.
Despite
promising
clinical
results,
adherence
potential
deficiencies
require
careful
follow-up
individualized
programming
monitored
by
specialists.
Future
research
should
elucidating
molecular
mechanisms
underlying
physiological
systems,
long-term
safety.
Nevertheless,
innovative
approach
offering
a
target-oriented
highly
effective
people
fighting
against
overweight
associated
medical
complications.
Obesity
multifactorial
chronic
numerous
comorbidities;
given
increasing
prevalence,
personalized
intervention
are
crucial
inhibit
"obesity
pandemic"
according
"food
re-educational"
protocol.
Among
dietary
interventions,
diet
(KD)
has
attracted
attention
effectiveness
weight
management
benefits.
A
variant,
very
low-calorie
(VLCKD),
more
recently
defined
low-energy
(VLEKD),
combines
benefits
ketosis
substantial
calorie
restriction,
improving
overall
health.
Язык: Английский
Ketogenic diets in chronic kidney disease patients: a review for skeptics by skeptics
Journal of Nephrology,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 30, 2025
Abstract
Over
the
last
few
decades,
there
has
been
growing
interest
in
use
of
ketogenic
diets,
mainly
as
a
weight
loss
strategy.
Obesity
and
diabetes
are
major
risk
factors
for
kidney
disease,
obese
patients
with
chronic
disease
(CKD)
potential
candidates
reducing
among
them
diets.
Of
further
relevance
to
nephrology,
limited
number
recent
studies
suggests
favorable
effect
diets
affected
by
autosomal
dominant
polycystic
(ADPKD).
However,
concerns
remain
about
safety
CKD,
particularly
long
term
those
poor
residual
function.
The
confusion
surrounding
definition
adds
these
concerns.
aim
this
review
is
summarize
information
on
main
types
used
daily
practice
discuss
options
their
implementation
CKD
patients,
limiting
ultra-processed
or
industrial
preparations.
Although
needed
identify
profile
who
may
benefit
from
treat
obesity
slow
progression
ADPKD,
assess
short-
long-term
adherence,
available
data
appear
promising.
This
critical
intended
stimulate
research.
Graphical
abstract
Язык: Английский